Atossa is focused on helping address significant unmet needs across the continuum of breast cancer.
1-in-8 women experience breast cancer.
2nd leading cause of cancer death in American women.
Around 170,000 women in the U.S are living with metastatic breast cancer.
About 20% to 30% of women with early-stage cancer later develop metastatic breast cancer.
(Z)-endoxifen is a powerful selective estrogen receptor modulator (SERM) that has been developed to be nearly 100 times more potent than other SERMs, with a potentially improved tolerability profile.
(Z)-endoxifen has demonstrated broad utility across the entire breast cancer treatment paradigm, and Atossa is advancing (Z)-endoxifen to target multiple breast cancer settings, including metastatic breast cancer.
Learn about (Z)-endoxifen and our focus to advance its development for metastatic breast cancer and other high need breast cancer indications.